Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Reference69 articles.
1. Food and Drug Administration (2018) Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. US department of health and human services. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics
2. Serugal B, Ocana A, Amir E et al (2015) Failures in phase III: causes and consequences. Clin Cancer Res 21(20):4552–4560. https://doi.org/10.1158/1078-0432.CCR-15-0124
3. Douaiher J, Ravipati A, Chowdhury S (2017) Colorectal cancer–global burden, trends, and geographical variations. J Surg Oncol 115:619–630. https://doi.org/10.1002/jso.24578
4. Schwartzberg LS, Rivera F, Karthaus M et al (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32(21):2240–2247. https://doi.org/10.1200/JCO.2013.53.2473
5. Stintzing S, Modest DP, Rossius L et al (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17:1426–1434. https://doi.org/10.1016/S1470-2045(16)30269-8
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献